DiaMedica Therapeutics Reports Q2 2026 Financial Results

What Happened
DiaMedica Therapeutics, Inc. (DMAC) announced on August 10, 2026 that it has released its condensed consolidated financial results for the quarter ended June 30, 2026. The company furnished a press release with a business update and its second‑quarter 2026 financial results as Exhibit 99.1 to the Current Report on Form 8‑K.

Key Details

• Filing date: August 10, 2026 (Current Report on Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Exhibit: Press release providing a business update and Q2 2026 financial results furnished as Exhibit 99.1 and incorporated by reference.
• No other material events (e.g., executive changes, mergers, bankruptcies) were reported in this filing.

Why It Matters
This 8‑K signals that DiaMedica has published its quarterly earnings information—key data investors use to assess performance such as revenue, net income/loss, R&D spending and cash position. Retail investors should review the attached press release (Exhibit 99.1) or the company’s investor relations page for the specific financial metrics and any commentary management provided about business trends or outlook.